Form 13-F position report

CYMABAY THERAPEUTICS INC

Reported by TWO SIGMA ADVISERS LP

CBAY CUSIP 23257D103 Manager CIK 0001478735

Reported 0 shares, down 120,200 (100.0%) from the prior quarter.

Reported value -100.0%; share count -100.0% vs. the prior quarter.

Reduced
% of reported 13F value 0 This manager · Q1 2024
Shares 0 Quarter-end amount reported
Reported value $0 Fair value at quarter end
Consecutive quarters held 18 Through Q1 2024

Reported position value by quarter

Reported position value by quarter

Each bar is a Form 13-F quarter-end snapshot. It does not show trades made within the quarter.

Reported position value by quarter
Date Holding Value
2021-12-31 633000
2022-03-31 395000
2022-06-30 435000
2022-09-30 1329000
2022-12-31 2530183
2023-03-31 12337387
2023-06-30 12662996
2023-09-30 9960447
2023-12-31 2839124
2024-03-31 0

Quarterly position history

How this manager's reported quarter-end position changed over time.

10 quarters
Quarterly reported position history for CYMABAY THERAPEUTICS INC held by TWO SIGMA ADVISERS LP.
Quarter Activity Shares Change % of reported 13F Reported value Filed Source filing
Q1 2024 Reduced 0 -120,200 (-100.0%) 0 $0 2024-05-15
Q4 2023 Reduced 120,200 -547,838 (-82.0%) < 0.01% $2,839,124 2024-02-14
Q3 2023 Reduced 668,038 -488,400 (-42.2%) 0.03% $9,960,447 2023-11-14
Q2 2023 Reduced 1,156,438 -258,400 (-18.3%) 0.03% $12,662,996 2023-08-14
Q1 2023 Added 1,414,838 +1,011,300 (250.6%) 0.03% $12,337,387 2023-05-15
Q4 2022 Added 403,538 +23,700 (6.2%) < 0.01% $2,530,183 2023-02-14
Q3 2022 Added 379,838 +232,300 (157.5%) < 0.01% $1,329,000 2022-11-14
Q2 2022 Added 147,538 +20,500 (16.1%) < 0.01% $435,000 2022-08-15
Q1 2022 Reduced 127,038 -60,100 (-32.1%) < 0.01% $395,000 2022-05-16
Q4 2021 Reduced 187,138 -196,600 (-51.2%) < 0.01% $633,000 2022-02-14
Five years are shown. A free account unlocks the complete reported history. Unlock full history

Who else reported the position

200 managers reported CYMABAY THERAPEUTICS INC for Q1 2024.

Managers reporting CYMABAY THERAPEUTICS INC in Q1 2024.
Manager Activity Shares Change % of reported 13F Reported value Tenure
IFP Advisors Inc Unchanged 650 0 < 0.01% $21,077 19 qtrs
VICTORY CAPITAL MANAGEMENT INC Reduced 0 -689,603 0 $0 5 qtrs
Hennion & Walsh Asset Management Inc Reduced 0 -78,311 0 $0 4 qtrs
Metropolitan Life Insurance Co NY Reduced 0 -6,447 0 $0 4 qtrs
Novo Holdings A S Reduced 0 -900,000 0 $0 4 qtrs
J Goldman & Co LP Reduced 0 -165,937 0 $0 3 qtrs
Harvest Fund Management Co Ltd Reduced 0 -1,076 0 $0 2 qtrs
SUSQUEHANNA INTERNATIONAL GROUP LLP Reduced 0 -68,457 0 $0 20 qtrs
AMERIPRISE FINANCIAL INC Reduced 0 -25,711 0 $0 2 qtrs
Verition Fund Management LLC Reduced 0 -10,170 0 $0 8 qtrs
Premium adds each manager's conviction percentile across reporting peers.
Filing details and methodology As reported
Report period
March 31, 2024
Filed
May 15, 2024
Filing type
13F-HR
Position type
COM

Voting authority reported

No voting-authority amounts were reported for this position. Voting authority is not required for reported call options.

Form 13-F is a delayed quarter-end snapshot of disclosed long Section 13(f) securities. It can be filed up to 45 days after quarter end, excludes short positions and most non-U.S. securities, and does not reveal intra-quarter trading. For options, reported shares and value describe the underlying-share exposure; strike, expiry, premium, and written positions are not disclosed.